Open access
Aug 2026
Real-World Outcomes of Baricitinib in Patients with Rheumatoid Arthritis: A Two-Year Observational Study of Overall and Difficult-to-Treat Patients in Japan.
Baricitinib showed sustained effectiveness and retention, including in patients with D2T RA; early improvements in pain and fatigue were predictive of CDAI disease remission during the 24-month follow-up.
Kei Ikeda, Taisuke Kojima, Naoto Tsujimoto et al.
· Modern Rheumatology · 0 citations